InvestorsHub Logo
Post# of 252477
Next 10
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

Re: masterlongevity post# 209482

Tuesday, 02/28/2017 7:41:33 PM

Tuesday, February 28, 2017 7:41:33 PM

Post# of 252477
Kyprolis is about a $800m/year product right now, and that's without any convincing trial showing superiority over Velcade. So I think this new trial should produce some growth.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.